In addition to impairing DNA repair, PARP1/PARP2 inhibitors—which are in clinical use against a growing list of cancers—trap the abundant PARP1 protein on DNA breaks, which has genotoxic cytotoxic consequences, especially in BRCA1- or BRCA2-deficient cancers7,8. The gene discussed is PARP1; the disease is cancer.